Goddard Philippa
Department of Clinical Chemistry, Birmingham Children's Hospital.
J Fam Health Care. 2004;14(4):90-2.
The Department of Health and the National Screening Committee are funding a new newborn screening service for the rare inherited disorder medium chain acyl-CoA dehydrogenase deficiency, otherwise known as MCADD. Screening commenced as a pilot programme on 1 March 2004 from six laboratories in England. An evaluation study following all positive cases of MCADD from this first two-year pilot period will continue for a further three years to measure the overall effectiveness of screening for MCADD in the UK. This article reviews the background to the introduction of the pilot programme and describes the features and complications of MCADD, including the diagnosis and management.
卫生部和国家筛查委员会正在资助一项针对罕见遗传性疾病中链酰基辅酶A脱氢酶缺乏症(又称MCADD)的新生儿筛查新服务。筛查于2004年3月1日作为试点项目在英格兰的六个实验室启动。对这第一个为期两年的试点阶段所有MCADD阳性病例的评估研究将再持续三年,以衡量在英国进行MCADD筛查的总体效果。本文回顾了引入试点项目的背景,并描述了MCADD的特征和并发症,包括诊断和管理。